April 2016: United States / FDA
Consultation Response
Missing the point: a response to Matt Myers’ views on priorities for FDA
An e-letter in Tobacco Control criticising Myers’ trivial and largely irrelevant criticisms of FDA when much greater issues demand the attention of both FDA and Congress.